Literature DB >> 22402256

Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.

Beata Seeber1, Stephanie C Ziehr, Andreas Gschlieβer, Aandrea Gschliesser, Christina Moser, Verena Mattle, Christoph Seger, Andrea Griesmacher, Nicole Concin, Hans Concin, Ludwig Wildt.   

Abstract

BACKGROUND: The levonorgestrel-releasing intrauterine system (LNG-IUS) is well accepted as an easy-to-use contraceptive with an excellent side-effect profile. It contains a reservoir of 52 mg of levonorgestrel (LNG) with continuous release of the steroid. Its contraceptive use is approved for 5 years. The aim of this study was to determine the plasma concentration of LNG and its variation with time in patients with in-dwelling LNG-IUS Mirena®. STUDY
DESIGN: In this study, we determined LNG plasma concentrations in 110 women with LNG-IUS at different time points of use. Time from insertion of the system in the study population ranged from 20 days to 11.1 years. Quantitative LNG levels were determined using a validated liquid chromatography-tandem mass spectrometry assay.
RESULTS: The mean±SD LNG plasma level in all women was 147±59 pg/mL. A highly significant negative correlation between LNG plasma level and LNG-IUS time of use could be demonstrated. In the first year of use, LNG plasma level was as high as 191±71 pg/mL, decreasing to 157±68 pg/mL in the second year and 134±41 pg/mL in the third year. Even after exceeding the recommended period of LNG-IUS use, systemic LNG concentrations were detectable: 133±38 pg/mL in the sixth year, 133±48 pg/mL in the seventh year and 117±45 pg/mL in the eighth year. Furthermore, a significant negative correlation between LNG plasma level and body mass index could be shown.
CONCLUSION: Systemic LNG concentrations can be found in all patients with LNG-IUS IUS. However, concentrations are much lower than in other forms of LNG application. Moreover, this study demonstrates that a systemic effect of LNG-IUS can also be found after the recommended contraceptive lifespan of 5 years.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22402256     DOI: 10.1016/j.contraception.2012.01.015

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study.

Authors:  Lene Andersen; Søren Friis; Jesper Hallas; Pernille Ravn; Bjarne W Kristensen; David Gaist
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

2.  CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception.

Authors:  Gaia Sciaranghella; Cuiwei Wang; Haihong Hu; Kathryn Anastos; Zaher Merhi; Marek Nowicki; Frank Z Stanczyk; Ruth M Greenblatt; Mardge Cohen; Elizabeth T Golub; D Heather Watts; Galit Alter; Mary A Young; Athe M N Tsibris
Journal:  J Infect Dis       Date:  2015-04-20       Impact factor: 5.226

3.  Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review.

Authors:  Shaalini Ramanadhan; William J Jusko; Alison Edelman
Journal:  Curr Obstet Gynecol Rep       Date:  2020-05-04

4.  Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System.

Authors:  Kay J Park; Vance Broach; Dennis S Chi; Irina Linkov; Frank Z Stanczyk; Prusha Patel; Anjali Jotwani; Celeste Leigh Pearce; Malcolm C Pike; Noah D Kauff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-09-02       Impact factor: 4.090

Review 5.  Clarification of contraceptive drug pharmacokinetics in obesity.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-08-16       Impact factor: 3.375

6.  Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding.

Authors:  Pallavi C Dhamangaonkar; K Anuradha; Archana Saxena
Journal:  J Midlife Health       Date:  2015 Jan-Mar

Review 7.  Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Jennifer A Hurlburt; Gustavo F Doncel
Journal:  Int J Womens Health       Date:  2013-10-21

8.  Dendritic cell function and pathogen-specific T cell immunity are inhibited in mice administered levonorgestrel prior to intranasal Chlamydia trachomatis infection.

Authors:  Nirk E Quispe Calla; Rodolfo D Vicetti Miguel; Ao Mei; Shumin Fan; Jocelyn R Gilmore; Thomas L Cherpes
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

9.  Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling.

Authors:  Moazzam Ali; Luis Bahamondes; Sihem Bent Landoulsi
Journal:  Glob Health Sci Pract       Date:  2017-12-28

10.  Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives.

Authors:  Andrea J Rapkin; Yelena Korotkaya; Kathrine C Taylor
Journal:  Open Access J Contracept       Date:  2019-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.